Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Tubulis
Biotech
Biotech's top money raisers: 2025
While 2024 marked the return of the biotech megaround, 2025 proved that it wasn’t just a one-year anomaly.
Gabrielle Masson
Mar 2, 2026 6:30am
Former Roche oncology head turns to Tubulis—Chutes & Ladders
Jan 9, 2026 8:30am
ESMO: Tubulis' next-gen ADC lives up to hype with 59% ORR
Oct 19, 2025 4:15am
Tubulis touts $361M series C as next-gen ADC data drop nears
Oct 15, 2025 5:01am
Takeda taps longtime Lilly exec as US head—Chutes & Ladders
Sep 12, 2025 8:30am
J&J vet jumps to Affinia—Chutes & Ladders
Feb 7, 2025 8:30am